secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001437749-26-004954
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex wins Japanese and European patent grants for REQORSA combos; Acclaim-3 update
--------------------------------------------------------------------------------

- Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA + PD-L1 antibodies.
- European Patent Office granted patent for REQORSA + PD-1 antibodies to treat cancer.
- Acclaim-3 Phase 2 expansion: enrollment of first 25 patients for interim analysis expected by H1 2026; interim analysis in H2 2026.
- Phase 2 primary endpoint: 18-week progression-free survival rate; trial targets ~50 patients with ES-SCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/0001437749-26-004954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/gnpx20260220_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-004954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer